Thermo Fisher (0R0H) Share Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0R0H Analyst Ratings

Strong Buy

14 Buy

3 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Thermo

Fisher

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0R0H Stock 12 Month Forecast

Average Price Target

$758.47

▲(24.99% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Thermo Fisher in the last 3 months. The average price target is $758.47 with a high forecast of $830.00 and a low forecast of $575.00. The average price target represents a 24.99% change from the last price of $606.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"468":"$468","831":"$831","558.75":"$558.8","649.5":"$649.5","740.25":"$740.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":830,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$830.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":758.470588235294,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$758.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$575.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[468,558.75,649.5,740.25,831],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,657.499,670.7683076923078,684.0376153846154,697.3069230769231,710.5762307692307,723.8455384615385,737.1148461538462,750.3841538461538,763.6534615384616,776.9227692307693,790.1920769230769,803.4613846153846,816.7306923076923,{"y":830,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,657.499,665.2660452488687,673.0330904977376,680.8001357466063,688.5671809954752,696.3342262443439,704.1012714932126,711.8683167420814,719.6353619909502,727.402407239819,735.1694524886877,742.9364977375565,750.7035429864253,{"y":758.470588235294,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,657.499,651.1529230769231,644.8068461538462,638.4607692307693,632.1146923076923,625.7686153846154,619.4225384615385,613.0764615384616,606.7303846153847,600.3843076923077,594.0382307692307,587.6921538461538,581.3460769230769,{"y":575,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":521.192,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":566.944,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":583.337,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":581.22,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":581.021,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":508.318,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":495.845,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.93,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":493.529,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":513.356,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":573.468,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":601.147,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":657.499,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$830.00

Average Price Target$758.47

Lowest Price Target$575.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Toung

Argus Research

$560→$780

Buy

28.54%

Upside

Assigned

10/29/26

Thermo Fisher price target raised to $780 from $560 at ArgusThermo Fisher price target raised to $780 from $560 at Argus

Jill Wu

CMB International Securities

$660→$800

Buy

31.84%

Upside

Reiterated

10/23/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)

Patrick B Donnelly

Citi

$685→$800

Buy

31.84%

Upside

Reiterated

10/23/26

Thermo Fisher price target raised to $800 from $685 at CitiThermo Fisher price target raised to $800 from $685 at Citi

Aristotelis Moutopoulos

DZ BANK AG

$630→$650

Hold

7.12%

Upside

Downgraded

10/23/26

Thermo Fisher downgraded to Hold from Buy at DZ BankThermo Fisher downgraded to Hold from Buy at DZ Bank

Daniel Brennan

TD Cowen

$760→$810

Buy

33.48%

Upside

Assigned

10/22/26

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO) and Telix Pharmaceuticals (Other OTC: TLPPF)

Doug Schenkel

UBS

$800

Buy

31.84%

Upside

Reiterated

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Perrigo Company (NYSE: PRGO), Thermo Fisher (NYSE: TMO) and Medpace Holdings (NASDAQ: MEDP)

Dan Leonard

RBC Capital

$580→$730

Hold

20.30%

Upside

Assigned

10/22/26

RBC Capital Reaffirms Their Hold Rating on Thermo Fisher (TMO)

Luke Sergott

Barclays

$750→$775

Buy

27.72%

Upside

Reiterated

10/22/26

Barclays Sticks to Its Buy Rating for Thermo Fisher (TMO)

Catherine Ramsey Schulte

Robert W. Baird

$723→$756

Buy

24.59%

Upside

Reiterated

10/22/26

Thermo Fisher price target raised to $756 from $723 at BairdThermo Fisher price target raised to $756 from $723 at Baird

Casey Woodring

J.P. Morgan

$760→$820

Buy

35.13%

Upside

Reiterated

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (Other OTC: RHHVF), Thermo Fisher (NYSE: TMO) and Argenx Se (NASDAQ: ARGX)

Daniel Arias

Stifel Nicolaus

$650→$775

Buy

27.72%

Upside

Reiterated

10/22/26

Thermo Fisher price target raised to $775 from $650 at StifelThermo Fisher price target raised to $775 from $650 at Stifel

‏Avantika Dhabaria‏

Bank of America Securities

$795

Buy

31.01%

Upside

Reiterated

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (NYSE: TMO) and Molina Healthcare (NYSE: MOH)

Evie Koslosky

Goldman Sachs

$780→$830

Buy

36.78%

Upside

Reiterated

10/21/26

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO) and Zimmer Biomet Holdings (NYSE: ZBH)

Eve Burstein

Bernstein

$575

Hold

-5.24%

Downside

Assigned

10/19/26

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (NASDAQ: PTCT), Immunovant (NASDAQ: IMVT) and Thermo Fisher (NYSE: TMO)

Kallum Titchmarsh

Morgan Stanley

$650→$730

Buy

20.30%

Upside

Assigned

10/13/26

Thermo Fisher price target raised to $730 from $650 at Morgan StanleyThermo Fisher price target raised to $730 from $650 at Morgan Stanley

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Toung

Argus Research

$560→$780

Buy

28.54%

Upside

Assigned

10/29/26

Thermo Fisher price target raised to $780 from $560 at ArgusThermo Fisher price target raised to $780 from $560 at Argus

Jill Wu

CMB International Securities

$660→$800

Buy

31.84%

Upside

Reiterated

10/23/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)

Patrick B Donnelly

Citi

$685→$800

Buy

31.84%

Upside

Reiterated

10/23/26

Thermo Fisher price target raised to $800 from $685 at CitiThermo Fisher price target raised to $800 from $685 at Citi

Aristotelis Moutopoulos

DZ BANK AG

$630→$650

Hold

7.12%

Upside

Downgraded

10/23/26

Thermo Fisher downgraded to Hold from Buy at DZ BankThermo Fisher downgraded to Hold from Buy at DZ Bank

Daniel Brennan

TD Cowen

$760→$810

Buy

33.48%

Upside

Assigned

10/22/26

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO) and Telix Pharmaceuticals (Other OTC: TLPPF)

Doug Schenkel

UBS

$800

Buy

31.84%

Upside

Reiterated

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Perrigo Company (NYSE: PRGO), Thermo Fisher (NYSE: TMO) and Medpace Holdings (NASDAQ: MEDP)

Dan Leonard

RBC Capital

$580→$730

Hold

20.30%

Upside

Assigned

10/22/26

RBC Capital Reaffirms Their Hold Rating on Thermo Fisher (TMO)

Luke Sergott

Barclays

$750→$775

Buy

27.72%

Upside

Reiterated

10/22/26

Barclays Sticks to Its Buy Rating for Thermo Fisher (TMO)

Catherine Ramsey Schulte

Robert W. Baird

$723→$756

Buy

24.59%

Upside

Reiterated

10/22/26

Thermo Fisher price target raised to $756 from $723 at BairdThermo Fisher price target raised to $756 from $723 at Baird

Casey Woodring

J.P. Morgan

$760→$820

Buy

35.13%

Upside

Reiterated

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (Other OTC: RHHVF), Thermo Fisher (NYSE: TMO) and Argenx Se (NASDAQ: ARGX)

Daniel Arias

Stifel Nicolaus

$650→$775

Buy

27.72%

Upside

Reiterated

10/22/26

Thermo Fisher price target raised to $775 from $650 at StifelThermo Fisher price target raised to $775 from $650 at Stifel

‏Avantika Dhabaria‏

Bank of America Securities

$795

Buy

31.01%

Upside

Reiterated

10/22/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (NYSE: TMO) and Molina Healthcare (NYSE: MOH)

Evie Koslosky

Goldman Sachs

$780→$830

Buy

36.78%

Upside

Reiterated

10/21/26

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO) and Zimmer Biomet Holdings (NYSE: ZBH)

Eve Burstein

Bernstein

$575

Hold

-5.24%

Downside

Assigned

10/19/26

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (NASDAQ: PTCT), Immunovant (NASDAQ: IMVT) and Thermo Fisher (NYSE: TMO)

Kallum Titchmarsh

Morgan Stanley

$650→$730

Buy

20.30%

Upside

Assigned

10/13/26

Thermo Fisher price target raised to $730 from $650 at Morgan StanleyThermo Fisher price target raised to $730 from $650 at Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARDXArdelyx

PVLAPalvella Therapeutics

CELCCelcuity

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Thermo Fisher

3 Months

Daniel AriasStifel Nicolaus

Success Rate

22/30 ratings generated profit

Average Return

+5.19%

Copying Daniel Arias's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +5.19% per trade.

1 Year

Doug SchenkelUBS

Success Rate

18/19 ratings generated profit

Average Return

+21.96%

Copying Doug Schenkel's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +21.96% per trade.

2 Years

Doug SchenkelUBS

Success Rate

18/19 ratings generated profit

Average Return

+43.90%

Copying Doug Schenkel's trades and holding each position for 2 Years would result in 94.74% of your transactions generating a profit, with an average return of +43.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0R0H Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0R0H has received 23 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 0R0H average Analyst price target in the past 3 months is 758.47.

Each month's total comprises the sum of three months' worth of ratings.

0R0H Financial Forecast

0R0H Earnings Forecast

Next quarter’s earnings estimate for 0R0H is $7.14 with a range of $7.00 to $7.34. The previous quarter’s EPS was $6.68. 0R0H beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0R0H has Performed in-line its overall industry.

0R0H Sales Forecast

Next quarter’s sales forecast for 0R0H is $12.85B with a range of $12.71B to $12.99B. The previous quarter’s sales results were $12.14B. 0R0H beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0R0H has Performed in-line its overall industry.

0R0H Stock Forecast FAQ

What is GB:0R0H’s average 12-month price target, according to analysts?

Based on analyst ratings, Thermo Fisher’s 12-month average price target is 758.47.

What is GB:0R0H’s upside potential, based on the analysts’ average price target?

Thermo Fisher has 24.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Thermo Fisher a Buy, Sell or Hold?

Thermo Fisher has a consensus rating of Strong Buy, which is based on 14 buy ratings, 3 hold ratings and 0 sell ratings.

What is Thermo Fisher’s share price target?

The average share price target for Thermo Fisher is 758.47. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $830.00 ,and the lowest forecast is $575.00. The average share price target represents 24.99% Increase from the current price of $606.81.

What do analysts say about Thermo Fisher?

Thermo Fisher’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of Thermo Fisher?

To buy shares of GB:0R0H, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Thermo Fisher (0R0H) Share Forecast & Price Target

0R0H Analyst Ratings

0R0H Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Thermo Fisher

0R0H Analyst Recommendation Trends

0R0H Financial Forecast

0R0H Earnings Forecast

0R0H Sales Forecast

0R0H Stock Forecast FAQ

Detailed List of Analyst Forecasts